Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
- PMID: 36311966
- PMCID: PMC9589137
- DOI: 10.22037/ghfbb.v15i3.2549
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
Abstract
Non-alcoholic fatty liver disease is one of the main liver diseases worldwide. The most common cause of death in patients with non-alcoholic fatty liver disease is cardiovascular disease. The relationship between these two conditions has been well established. Indeed, identical reasons may contribute to the development of cardiovascular disease and non-alcoholic fatty liver disease with lifestyle factors such as smoking, sedentariness, poor nutritional habits, and physical inactivity being major aspects. This review focuses on potential pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver. PubMed, EMBASE, Orphanet, MIDLINE, Google Scholar, and Cochrane Library were searched for articles published between 2006 and 2022. Relevant articles were selected using the following terms: "Non-alcoholic fatty liver disease," "Сardiovascular diseases," "Pathophysiological mechanisms." The reference lists of all identified articles were searched for other relevant publications as well. The pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver remain largely speculative and may include systemic low-grade inflammation, atherogenic dyslipidemia, abnormal glucose metabolism and hepatic insulin resistance, endothelial dysfunction, gut dysbiosis, as well as the associated cardiac remodeling, which are influenced by interindividual genetic and epigenetic variations. It is clear that the identification of pathophysiological mechanisms underlying cardiovascular disorders in non-alcoholic fatty liver disease will make the selection of therapeutic measures more optimal and effective.
Keywords: Cardiovascular diseases; Non-alcoholic fatty liver disease; Pathophysiological mechanisms.
©2022 RIGLD, Research Institute for Gastroenterology and Liver Diseases.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures
Similar articles
-
Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".Hepat Mon. 2014 May 1;14(5):e17641. doi: 10.5812/hepatmon.17641. eCollection 2014 May. Hepat Mon. 2014. PMID: 24829591 Free PMC article. Review.
-
Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis.World J Hepatol. 2016 Jun 8;8(16):665-72. doi: 10.4254/wjh.v8.i16.665. World J Hepatol. 2016. PMID: 27326313 Free PMC article. Review.
-
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.Front Med (Lausanne). 2019 Sep 13;6:202. doi: 10.3389/fmed.2019.00202. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31616668 Free PMC article. Review.
-
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations.J Clin Med. 2021 Jan 26;10(3):467. doi: 10.3390/jcm10030467. J Clin Med. 2021. PMID: 33530440 Free PMC article. Review.
-
Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.Cas Lek Cesk. 2022 Spring;161(2):65-71. Cas Lek Cesk. 2022. PMID: 35728960 English.
Cited by
-
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD).Eur J Med Res. 2023 Apr 17;28(1):153. doi: 10.1186/s40001-023-01114-6. Eur J Med Res. 2023. PMID: 37062837 Free PMC article.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk.Biomolecules. 2025 Jan 22;15(2):163. doi: 10.3390/biom15020163. Biomolecules. 2025. PMID: 40001466 Free PMC article. Review.
-
Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: A Bidirectional Association Based on Endothelial Dysfunction.Int J Mol Sci. 2024 Oct 1;25(19):10595. doi: 10.3390/ijms251910595. Int J Mol Sci. 2024. PMID: 39408924 Free PMC article. Review.
-
Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages.Antioxidants (Basel). 2023 Mar 13;12(3):711. doi: 10.3390/antiox12030711. Antioxidants (Basel). 2023. PMID: 36978959 Free PMC article.
-
System failure: Systemic inflammation following spinal cord injury.Eur J Immunol. 2024 Jan;54(1):e2250274. doi: 10.1002/eji.202250274. Epub 2023 Oct 19. Eur J Immunol. 2024. PMID: 37822141 Free PMC article. Review.
References
-
- Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–30. - PubMed
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. - PubMed
-
- Ivashkin VT, Mayevskaya MV, Pavlov ChS, Tikhonov IN, Shirokova YeN, Buyeverov AO, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Rus J gastroenterol hepatol coloproctol. 2016;26:24–42.
-
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402. - PubMed
-
- Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. 2021;54:1013–1025. - PubMed
Publication types
LinkOut - more resources
Full Text Sources